Experimental and clinical studies on the formation of antibodies to neocarzinostatin, a new protein antibiotic.
The injection of clinical doses of neocarzinostatin (NCS) in guinea pigs did not result in antibody formation as judged by immunoelectrosyneresis, micro-Ouchterlony agar diffusion, fluorescence polarization, and passive cutaneous anaphylaxis reaction. This confirmed previous work on passive hemagglutination and passive cutaneous anaphylaxis reaction in a heterocytotropic system in guinea pigs. Forty-eight serum samples from 28 patients who were previously treated with NCS alone (8--161 mg) for a period of 8-85 days did not show any sign of antibody formation as revealed by immunoelectrosyneresis, micro-Ouchterlony agar diffusion, and fluorescence polarization techniques. In a homocytotropic system, the passive cutaneous anaphylaxis reaction was carried out with sera of sensitized guinea pigs and test guinea pigs which revealed that no IgE and IgA antibody to NCS was present in the sensitized sera. Those patients with bladder cancer who did not respond to NCS therapy or exhibit any side effects even after 21 mg were found to have proteolytic activity in their sera which degraded NCS very rapidly as revealed by the fluorescence polarization technique.
D000707:Anaphylaxis / Q000209:etiology; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000276:immunology*; D000917:Antibody Formation; D000941:Antigens / Q000008:administration & dosage; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D010447:Peptide Hydrolases / Q000097:blood; D012882:Skin Tests; D009353:Zinostatin / Q000276:immunology* / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D000941:Antigens; D009353:Zinostatin; D010447:Peptide Hydrolases